










The Centre for Health Economics Research and Evaluation (CHERE) was 
established in 1991.  CHERE is a centre of excellence in health economics and 
health services research. It is a joint Centre of the Faculties of Business 
and Nursing, Midwifery and Health at the University of Technology, Sydney, in 
collaboration with Central Sydney Area Health Service. It was established as a 
UTS Centre in February, 2002. The Centre aims to contribute to the development 
and application of health economics and health services research through 
research, teaching and policy support. CHERE’s research program encompasses 
both the theory and application of health economics. The main theoretical 
research theme pursues valuing benefits, including understanding what 
individuals value from health and health care, how such values should be 
measured, and exploring the social values attached to these benefits. The 
applied research  focuses on economic and the appraisal of new programs or new 
ways of delivering and/or funding services. CHERE’s teaching includes 
introducing clinicians, health services managers, public health professionals 
and others to health economic principles. Training programs aim to develop 
practical skills in health economics and health services research. Policy 
support is provided at all levels of the health care system by undertaking 
commissioned projects, through the provision of formal and informal advice as 



















University of Technology, Sydney 
City campus, Haymarket 
PO Box 123 Broadway NSW 2007 
Tel: +61 2 9514 4720  













Decisions about Pap tests: 




















  1.   Centre for Health Economics Research and Evaluation 
  Faculty  of  Business 
    University of Technology, Sydney 
 
2.  School of Economics 
    University of New South Wales 
 
A preliminary version of this paper was presented at the Australian Health Economics 
Society Conference held in Perth, September 2006. The research was supported by the 





Centre for Health Economics Research and Evaluation 
University of Technology, Sydney 
PO Box 123 




Ph:  +61 2 9514 4720 
Fax:  +61 2 9514 4730 
First Version:  September 2006 













Despite the success internationally of cervical screening programs debate continues about 
optimal program design. This includes increasing participation rates among under-
screened women, reducing unnecessary early re-screening, improving accuracy of and 
confidence in screening tests, and determining the cost-effectiveness of  program 
parameters, such as type of screening test, screening interval and target group.  For all 
these issues, information about consumer and provider preferences and insight into the 
potential impact of any change to program design on consumer and provider behaviour 
are essential inputs into evidence-based health policy decision making. This paper reports 
the results of discrete choice experiments to investigate women’s choices and providers’ 
recommendations in relation to cervical screening in Australia. Separate experiments 
were conducted with women and general practitioners, with attributes selected to allow 
for investigation of interaction between women’s and providers’ preferences and to 
determine how women and general practitioners differ in their preferences for common 
attributes. The results provide insight into the agency relationship in this context. Our 
results indicate a considerable commonality in preferences but the alignment was not 
complete. Women put relatively more weight on cost, chance of a false positive and if the 
recommended screening interval were changed to one year.  
 




Cervical cancer is one of the most preventable and curable forms of cancer. A cervical 
cancer may take 10 or more years to develop, during which time pre-cancerous 
changes can be detected by a Pap smear, also called a Pap test, allowing for early 
treatment with an excellent chance of a full recovery.  It is estimated that regular 
cervical screening can prevent more than 90% of cervical cancers. As a result, many 
countries have implemented cervical screening programs, such as the National 
Cervical Screening Program (NCSP) in Australia. Since the introduction of the NCSP, 
cervical cancer has fallen from the eighth to the fourteenth most common cancer 
among Australian women. Deaths from cervical cancer fell by 40% between 1986 and 
1998.  While the NCSP has been largely successful in achieving its objectives, there 
remain considerable health policy challenges in relation to cervical screening. These 
include increasing participation rates among under-screened women, reducing 
unnecessary early re-screening, improving the accuracy of and confidence in cervical 
screening tests, and determining the most cost-effective parameters for the screening 
program, such as type of screening test, screening interval, age to commence and age 
to cease screening.  
 
The impact of any changes to the screening program, such as an introduction of new 
screening technology or changes in screening interval, on costs and outcomes depends 
on how consumers and providers change their behaviour in response to the policy 
change.  In Australia’s NCSP, cervical screening is most commonly provided at a 
primary care encounter. The cervical screening decision occurs as a result of an 
interaction between a provider giving information and making a recommendation to a 
patient, who may or may not have been seeking a screening test. It is important to 
understand the context in which women are provided with advice by their general 
practitioner (GP) and ultimately make decisions about cervical screening. This is a 
complex interaction that will depend on characteristics of the woman and the GP, as 
well as the characteristics of different tests. 
 
Information about women’s and providers’ preferences and insight into the potential 
impact of any change to the current program on the behaviour of women and 
providers are essential inputs into evidence-based health policy decision making. 
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Existing data sources provide limited information for analysis of consumer and 
provider preferences for screening, or the likely behavioural responses to changes in 
policy parameters. Information about screening is collected by the NCSP through the 
registries, but these data provide aggregate level information only, and are limited to 
screened women who participate in the registries. The National Health Survey 
provides some information about screening behaviour, and allows analysis of 
screening choice based on personal characteristics (Belkar, et al., 2006). However, a 
limitation of such data is that they provide a single self-report observation of whether 
a woman has had a screening test within a particular interval, with no information 
about the context in which the decision to screen is made. Therefore, they have 
limited value in predicting behaviour in relation to different policy parameters, and 
limited scope to model interaction with providers. 
 
 
In this paper we use stated preference data from a discrete choice experiment (DCE) 
to evaluate consumers’ and providers’ preferences for attributes of alternative tests, 
proposed changes to policy recommendations and potential new technologies in 
relation to cervical screening.  Stated preference data are useful in settings and 
contexts where market or revealed preference data are not available, or where there is 
limited variability in market or revealed preference data. Both these situations 
frequently arise for health programs, particularly where there is innovation, or where 
policies change as is the case here. To predict demand for screening in different policy 
settings accurately, it is most valid to model jointly the preferences of consumers and 
providers. Typically, revealed preference data provide information about the ultimate 
choice made, but are less informative about the consumer-provider interaction that 
was the basis of this choice. Thus, a further advantage of the use of a choice 
experiment is that it provides the capacity to model and estimate these interactive 
relationships. 
 
Separate experiments were conducted with women and GPs to determine the impact 
of a common set of attributes on their choices and recommendations respectively.  
Further, the approach allows for characteristics of women to be incorporated in the 
choice situation presented to GPs and for characteristics of GPs, and their 
recommendations, to be incorporated in the choice situation presented to women. By 
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collecting stated preference data it is possible to compare the preferences of each 
group and to learn more about how they interact.  This approach has been applied 
elsewhere in modelling consumer demand where agency relationships are important 
(Bartels, et al., 2006), and we demonstrate here that DCEs provide a powerful tool to 
model the interaction between a doctor and their patient and to investigate the relevant 
policy issues in the specific context of cervical screening.  
 
 
2  Screening for cervical cancer 
2.1 Screening decision 
Factors that have been found to be relevant to women’s decisions about cervical 
screening include doctor’s recommendation, previous experience with detection of 
abnormalities and their follow-up, having a female doctor available and women’s 
knowledge of screening recommendations and perceptions of risk (Bush, 2000, 
Hennig and Knowles, 1990, McKie, 1993, Milburn and MacAskill, 1994). A key 
question is how important the provider’s recommendation is to the decision about 
whether to have a screening test.   
 
When making the decision to undertake cervical screening, the consumer faces 
choices about when to have the test and what type of test to have. This decision is 
made in the context of the advice from the provider, who is better informed about the 
health consequences of the choice. There is information asymmetry in this situation, 
and the incentives facing the provider may not be the same as those facing the 
consumer – for example, the provider may be influenced by factors such as risk of 
litigation or the provision of incentive payments to increase screening. Such a scheme 
has existed in Australia. Within this framework it is possible to ask whether the GP 
acts as a perfect agent for the consumer in the sense described by Culyer (1989). That 
is, does the GP recommend the choice that the consumer would make if she had full 
information?  Given the role of the provider in the screening decision, it is also 
important to examine the response of providers to policy parameters. 
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2.2 Screening interval 
The NCSP recommends that all women between the ages of 20-69 should have 
regular Pap smears every two years. Information about a women’s screening history 
and reminders to women are currently provided through cervical cytology registers as 
part of the NSCP. However, there is debate internationally about the appropriate 
screening interval and age range for screening (Bjorge, et al., 1994, Boyce, et al., 
1990, Cruickshank, et al., 1997, Grant, 1999, Law, et al., 1999, Van Wijngaarden and 
Duncan, 1993). The screening interval is three yearly in the United Kingdom. There 
have been suggestions that the screening interval could increase to five yearly for 
some women, particularly if such a change was combined with the introduction of 
HPV (human Papilloma virus) testing or, more recently, the HPV vaccine.  Changing 
the screening interval would affect the cost-effectiveness of the NCSP(Anderson, et 
al., 2004), but the impact depends in part on how any change in recommendations 
would affect participation in screening. Given that the 2 yearly screening interval has 
been long established and widely accepted by the community and providers, one 
possible concern is that a change in the recommended screening interval may 
undermine provider or consumer confidence in the screening interval, affecting 
participation rates.   
 
Australian studies suggest at least one third of women in Australia who had a negative 
smear have at least one further Pap smear before the recommended 24 months before 
re-screening has elapsed (Australian Institute of Health and Welfare, 2004, Australian 
Institute of Health and Welfare (AIHW), 1998, Mitchell, et al., 2000). Participation 
rates throughout Australia appear to be plateauing at 60-70% (DHAC, 2000). In 2002-
03 the age standardised screening rate in the target population of women aged 20-69 
was 60.7%  but rates of screening vary with factors such as age, socioeconomic status, 
indigeneity and country of origin (Australian Institute of Health and Welfare, 2005). 
Thus, confidence in the NCSP may already be fragile, and could be eroded further if 
additional changes to recommendations were made. Information about how changes 
to recommendations about screening interval and age range might influence choices 
and subsequent behaviour of providers and consumers is thus relevant to the 




2.3 New technologies 
While manual reading of a Pap smear is the current recommended screening 
technology, there have been a number of recent developments in cervical screening 
technology which aim to improve the detection of abnormalities and enhance the 
overall accuracy and value of screening. These new technologies are at different 
stages of development and none has yet been fully evaluated in terms of its potential 
role in a national screening program, either in Australia or overseas.  Nonetheless, 
some are currently available in Australia and have been actively marketed to women 
and providers. Liquid based cytology and automated screening both have been 
available in Australia for a number of years and are sometimes used as an adjunct to 
conventional manual reading. Women presenting for cervical screening may currently 
be offered one or both of these technologies in addition to a conventional Pap smear.  
As these are not covered by Medicare, the services attract an additional out-of-pocket 
fee. Applications have been made to the Medical Services Advisory Committee for 
listing of liquid based cytology and HPV testing on the Medicare Benefits Schedule, 
but neither has at yet been recommended.   
 
Liquid based cytology is the most widely available adjunct technology in Australia. It 
involves the use of liquid-based sample collection and automated slide preparation, 
designed to provide more representative samples of evenly dispersed cells. In the past 
decade, there has been growing concern from providers about litigation arising from 
cervical screening, in part due to perceptions about the accuracy of cervical screening 
(Mitchell, 1997). Estimates of the sensitivity and specificity of the conventional Pap 
smear vary from 55% to 80% for sensitivity and from 65% to 99.4% for specificity 
(Fahey, et al., 1995, Soost, et al., 1991, van Oortmarssen and Habbema, 1991).  
Systematic reviews have reported that liquid based cytology can increase the 
sensitivity of the Pap smear but there are no accurate estimates for specificity (Payne, 
et al., 2000). One reason for the increased use of adjunct technologies in Australia is 
the possibility that they may provide greater accuracy in screening, and that this may 
be attractive to providers concerned about litigation.  
 
However, there is some evidence that, while the new technologies increase the rate of 
detection of cervical abnormalities (Austin and Ramzy, 1998, Australian Health 
Technology Advisory Committee, 1998, Cuzick, 1999), these appear more likely to be 
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minor lesions such as atypia, minor non-specific changes and low grade CIN (ie 
CIN1), which are less likely to progress to cancer than higher grade lesions.   Ideally, 
new technologies should significantly enhance the detection of high grade CIN (CIN2 
and CIN3) but without undue over-detection of low grade lesions. It is important to 
assess the tradeoffs made by women and providers in assessing the value of increased 
accuracy in detecting high grade lesions relative to the increased possibility of 
detecting low grade lesions.  
 
2.4 Increasing participation consistent with the national recommendations 
As an adjunct to the NCSP, the Australian Government Department of Health and 
Ageing has introduced a range of incentives via the Practice Improvement Program 
(PIP) to encourage general practices to increase participation in cervical screening 
consistent with the nationally recommended guidelines, that is, to increase screening 
of under-screened women, and to maximize the proportion of the target population 
that are screened at the recommended interval.  The PIP Cervical Screening Incentive 
offers financial incentives to encourage GPs to take cervical smears from unscreened 
and under-screened women aged between 20 and 69 years  
(http://www.cervicalscreen.health.gov.au/internet/screening/publishing.nsf/Content/pr
ofessionals, accessed September 13, 2006). The PIP comprises a Sign-on Payment, a 
Service Incentive Payment (SIP) for each screen of a woman in the target age range 
who has not been screened in the past four years, and an Outcomes Payment that 
rewards practices that adopt a systematic approach to cervical screening, as measured 
by reaching the specified target screening rate. These incentives are all aimed at 
changing the behaviour of GPs in relation to cervical screening, for example, by 
increasing the rate of opportunistic screening.  
 
3  Discrete choice experiment  
3.1 Methods 
In DCEs the stated preferences of individuals are collected via surveys in which 
respondents are asked to make choices from a set of hypothetical but realistic 
alternatives. Respondents are asked to indicate which option among those presented in 
each scenario is preferred (that is, which they would choose if the options presented 
represented the available choice set, with a “none of these” option often allowed). 
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Each alternative is described in terms of its underlying attributes and these can be 
varied across the range of plausible and policy relevant levels. Attribute levels are 
varied independently, and so respondents are forced to make trade-offs between 
attributes; for example between a higher priced, more accurate test and a less costly 
but lower quality test.  Because the combination of attributes and levels is potentially 
very large, experimental design principles are used to generate a sample of choice sets 
with the appropriate statistical properties to allow the quantification of the effect of 
the attributes, independently and together, and to predict how people will choose 
under different circumstances. In order to increase the sample size in a cost-effective 
manner, each respondent is asked to perform not just one choice task as described 
above, but rather several such choice tasks, in each of which the respondent faced a 
new set of hypothetical alternatives. 
 
There are many advantages and opportunities associated with stated preference data 
generated by DCEs but their collection also comes with added responsibilities (Viney 
et al, 2002). The selection of the respondent sample and the development and testing 
of the survey instrument are issues in all survey-based research. In addition, 
conducting a DCE survey requires attention to the framing of choices in a realistic and 
useful way, the selection of attributes and levels that are credible and meaningful to 
respondents, and designing the choice sets in accordance with the principles of 
experimental design. 
 
3.2 Development of the choice experiment 
As cervical screening is undertaken at intervals that may be two years or more in 
length, it is appropriate to conceptualise the interaction as a “one-shot” interaction, 
where the GP makes the recommendation and the women makes the consumption 
decision in the same encounter. For the women, the decision is whether or not to have 
a cervical screening test and if so whether to have a standard Pap smear or an 
alternative test technology which may be available. For the provider, the decision to 
be modelled is whether to recommend a test at this encounter, and which combination 
of testing modalities to recommend.  
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The choice experiment involved the collection of stated preference data in 
experiments conducted on two independent samples: women in the target population, 
and GPs. The samples were independent in that the sample of general practitioners 
was not selected to be the actual providers to the women who responded to the survey, 
or vice versa.  Although the nature of the relationship between the provider and 
consumer (e.g. is this her usual GP?) is important in the analysis of interactive effects, 
this can be addressed within each survey by inclusion of consumer characteristics in 
the survey to providers and provider characteristics in the survey for consumers.  To 
address issues relating to the decision to have a first cervical screening test (an 
important policy question given the persistence of a group of women in the population 
who have never been screened), two separate experiments were designed for the 
women; for women who had and had not had a cervical screening test previously. In 
the current paper, analysis and results are only presented for the previously screened 
women.  
 
A feature of these particular choice experiments is that it was necessary to consider 
not only attributes of the alternatives (the screening tests), but also of the decision 
making context. That is, for a woman, the decision to screen depends on factors 
relating to the encounter that will be common across all screening tests available at 
the encounter, such as familiarity with the GP or the time since her last screening test. 
These factors are important because they may be the key determinants of participation 
in screening, and if they are not explicitly included in the experiment the responses 
may lead to inaccurate estimates of the impact of attributes of the screening test. They 
are also important because of their relevance to policy options available. Similar 
considerations apply for the GP in making a screening recommendation. Thus, the 
experiment included a set of context attributes which were common across all 
screening tests offered, and a set of alternative specific attributes, that varied across 
the tests offered.  The doctor attributes in the patient choice task are context attributes 
as they vary over scenarios but not over options.  That is, for any particular scenario, 
women are asked to choose between alternative tests but are given advice by the same 
doctor. Similarly patient attributes that appear in the doctor choice task vary over 
scenarios but not over alternative tests. Other context variables are provided by 




Tables 1 and 2 present examples of the choice sets faced by women and GPs 
respectively. Different variants of the choice tasks are generated by systematically 
varying attribute levels. From Tables 1 and 2, there is a choice between standard Pap 
tests and liquid based Pap tests, which potentially provide greater accuracy, but at a 
greater cost. Conditional on choosing one of the two different Pap tests, women are 
also asked whether they would have an additional HPV test. For both choice questions 
and for both sets of respondents, the recommendation of (Carson, 2000) is followed 
by including a reference alternative that is constant across all choice occasions and 
allows the respondents to choose not to be tested, in the case of women, and, not to 
recommend any test in the case of GPs. In general this adds to the realism of the 
choice tasks but, because of the importance of the regularity of screening and the 
potential impact of recommended intervals between screens, the presence of this “opt-
out” or “none” choice is an essential component of the choice task. 
 
The choice of attributes and levels in the experiment was determined on the basis of a 
review of literature relating to cervical screening decisions and provider 
recommendations, and consideration of the current policy context for the NCSP. The 
final set of attributes and levels was informed by the conduct of pilot studies 
conducted with 79 women in the target screening age range and 12 GPs, which tested 
the comprehensibility of the choice scenarios and attributes and the appropriateness of 
the range of levels. The stated preference analogue of poor-quality revealed 
preference data occurs when respondents are offered attribute levels over which they 
are unwilling to trade. From the pilots it was evident that too many levels had been 
chosen in defining the attribute for how overdue (according to the screening interval) 
a Pap test was for a woman was to be tested, and the number of levels was reduced. A 
further change was to reword this attribute so that it was described in terms of the 
number of years since the last screening test, rather than the actual screening interval 
relative to the recommended screening interval. Apart from this change the pilots 
confirmed the viability of the planned study (Fiebig and Hall, 2005).  
 
Tables 3 and 4 present the full list of attributes and levels in the experiment. For the 
women, the context attributes included characteristics of the GP (her familiarity with 
the GP, the sex of the GP, and whether the GP would receive any incentive payment 
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for a cervical screening test), the time (in years) since her last Pap test, the current 
national recommended screening interval (in years) and the doctor’s recommendation. 
There were two attributes that related to HPV testing, but these are not considered in 
the current analysis. For the GPs the context attributes included the reason for the 
consultation (specifically for a Pap test, for a general check-up, or for a minor or 
serious health problem), the familiarity of the doctor with the patient (eg whether they 
were a regular patient or a new patient), the age and socioeconomic status of the 
patient, the time in years since the patient’s last Pap test, the recommended screening 
interval and whether the GP would receive an incentive payment. The levels of 
incentive payment were no incentive payment, an incentive payment if the woman 
was overdue for a screen, an incentive payment for screening at the recommended 
interval and an incentive payment for reaching a screening target amongst the eligible 
population.  
 
 Most attributes are self-explanatory from the tables, but the cost attribute requires 
some explanation. In the Australian context, the liquid based test is not currently 
covered by the Medicare Benefits Schedule, and thus, is not refundable via Medicare. 
It is also widely known to be an add-on to the standard Pap test. Therefore, it 
appeared unrealistic that the liquid based test would be cheaper than the standard Pap 
test, so the attribute was constructed such that the levels defined the additional cost of 
the liquid based test relative to the cost of a standard test. Given the construction of 
the design, this approach resulted in three levels of cost appearing in the survey for 
the liquid based test ($20, $40 and $60), although these cost levels were paired with 
the cost of the standard test such that the additional cost ranged across all four levels 
($10 -$40).  
 
From Table 3 it can be seen that for the previously screened women there were 8 
context attributes (4 with 4 levels and 4 with 2 levels) and 3 alternative specific 
attributes, each with 4 levels. For the providers, there were 8 context attributes, all 
with four levels, and the same 3 alternative specific attributes. Thus, overall the full 
factorial for the women’s survey includes 4
4*4
2*4
3*2 alternatives, and 4
8*4
3*2 
alternatives. The design for this study was constructed using systematic techniques 
that have been developed to find optimal or near-optimal designs for choice 
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experiments; see for example Burgess and Street(Burgess and Street, 2003, Street and 
Burgess, 2004a, Street and Burgess, 2004b) 
The need to design for both the context and the alternative tests created an additional 
experimental design complexity. The optimal design for this specific choice problem 
is not known. Therefore a design strategy was devised that would ensure that the 
effect of the alternative specific attributes could be estimated independently of the 
context attributes (which are common to all alternatives offered in a choice set). The 
designs were constructed by finding separate optimal designs for the common 
attributes and the alternative specific attributes, and then combining these to create an 
overall design. In effect, this breaks the design problem down into two stages. In the 
first stage, the choice problem is characterized as the decision to screen/recommend 
screening, given the attributes of the choice context. In the second stage, the choice 
problem is characterized as which screening test to choose/recommend. Thus, each 
choice set from the design for the common attributes was combined with every choice 
set for the alternative specific attributes. This approach led to a final design of 512 
choice sets for each experiment (comprising 32 scenarios for the common attributes, 
and 16 choice sets for the alternative specific attributes. Each design was blocked into 
16 versions, each with 32 choice sets. Allocation of choice sets to versions was 
systematic to ensure that each version included all 32 scenarios for the common 
attributes. 
 
In addition to the choice sets, the women’s survey also included questions about 
socio-demographic characteristics and the woman’s cervical screening history. The 
GP survey also included questions about socio-demographic characteristics, practice 
characteristics, knowledge of and familiarity with cervical screening tests, and a series 
of attitudinal questions relating to the current screening guidelines, medico-legal 
concerns in relation to cervical screening and opportunistic screening.  
 
3.3 Recruitment and data 
Respondents for the women’s survey were randomly sampled from the NSW 
population, aged 18-69 and recruited via door to door recruitment with random start 
points. Recruitment of respondents and conduct of interviews was carried out by an 
external recruitment and data collection firm, Surveys Australia. Participants were 
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provided with a double movie pass in recognition of the time taken to complete the 
survey.  
 
Respondents for the GPs’ survey were randomly sampled from the Australian Medical 
Association contact list for GPs in NSW. Recruitment was via mail out of a self-
completed survey, with telephone follow-up. Participants in the GP survey were 
provided with a gift voucher in recognition of the time taken to complete the survey. 
Participants were given an information sheet and provided written consent to 
participate. Responses were anonymous. The study was approved by the University of 
Technology, Sydney Human Research Ethics Committee. Respondents were 
randomly allocated to versions of the survey.  
 
The total sample of women comprised 234 women, of whom 167 were in the sample 
of women who had previously had a cervical screening test (analysed in this paper), 
giving 5344 choice observations. The total sample of general practitioners comprised 
215 GPs, giving 6880 choice observations. Sociodemographic variables for each 
sample are summarised in Table 5.   
 
Table 6 summarises the choice frequencies in the survey. Women chose no test in 
37.3% of the choice sets, the standard Pap test in 39.1% of choice sets and the liquid 
based test in 23.7% of choice sets. GPs chose no test in 42.8% of choice sets, the 
standard Pap test in 32.4% of choice sets and the liquid based test in 24.7% of choice 
sets.  Apart from twelve women (ten of whom always chose the standard Pap test and 
two always chose the liquid based Pap test) and two GPs (one of whom always chose 
no test, and the other always chose the liquid based test), all other respondents were 
responsive to changes in the attributes in the choice sets.  However, 13.8%, 10.2% and 
26.3% of women never chose no test, the standard Pap test or the liquid based test 
respectively. The corresponding figures for general practitioners were 1.4%, 5.6% and 
22.3%. Thus, particularly for the liquid based test, the raw data suggest that a 
relatively high proportion of respondents in both samples had strong preferences 




4 Estimation  methods 
The statistical analysis of choice data relies on the random utility model (McFadden 
and Train, 2000) where each respondent faces a choice amongst J alternatives 
repeated under S scenarios or choice situations. The utility that individual i derives 
from alternative j in scenario s is composed of systematic and random components 
denoted by 
 
isj i isj isj X U ε β + ′ = ) 1 (  
 
where Xisj  is a K x 1 vector of explanatory variables and βi is a conformable vector of 
coefficients. 
 
Conditional on βi, and assuming the disturbance terms εisj to be identically and 
independently distributed (IID) as extreme value, the standard multinomial logit 
(MNL) specification results (Train, 2003).  The probability that individual i chooses j 



















Simplicity of estimation and interpretation are among the main advantages of this 
model but these come at the cost of some restrictive assumptions that may be 
unrealistic in many situations (Train, 2003).    
 
In general, variability (heterogeneity) among respondents is expected, for example 
because of differences in tastes and decision making processes. Therefore, 
respondents with the same observed characteristics may value and weight attributes of 
a product differently when making a decision. The MNL specification can be 
generalized to account for this heterogeneity by allowing components of coefficients 
(β) to randomly vary over individuals but not over the repeated choices made by an 
individual by setting: 
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where k β  is the mean parameter vector for the population and ωki is the individual 
specific deviation from the mean. In this random parameter framework there is 
flexibility in the choice of the distribution of ωki. Here they are assumed to follow 
standard normal distributions, independent of each other and of the εisj. This 
specification introduces error correlation across choice situations, accounting for the 
dependence structure in unobserved utility among the repeated choices of an 
individual which comes from the panel structure of the data. This would be expected, 
since the same unobserved factors affect a specific respondent, to a certain degree, 
over the repeated choices. MNL would not capture that dependence.  This correlation 
is not perfect because of the presence of the independent extreme value terms εisj. 
Even though the ωki are assumed to be independent, this specification also induces 
correlation across the alternatives in each choice situation as long as generic attributes 
appear in the utility specifications for these alternatives. 
 
Advances in computer power and simulation based methods have made the resultant 
random parameter or mixed logit (MXL) model computationally feasible to estimate 
and popular in empirical work (Hall, et al., 2006, Revelt and Train, 1998, Train, et al., 
1999). Estimation by maximum simulated likelihood (MSL) is undertaken using a 
program downloaded from Kenneth Train's website (Train, 2004). All estimation 
results reported below were generated using 1000 Halton draws to simulate the 
likelihood functions to be maximized (Train, 2003);  
 
We restrict our attention to the initial decision to choose or recommend a cervical 
screening test and which test to choose or recommend. Analysis of the second stage 
decision to choose or recommend an HPV test will be pursued in later work.  Because 
the model specification is similar for both women and GPs (albeit with a different set 
of explanatory variables for each) they are discussed together below. In each of 32 
choice tasks, the respondent was asked either to choose (for the women) or 
recommend (for the GPs) between three different alternatives: a standard Pap test, a 
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liquid based Pap test or no test. The utility that individual i derives from 
choosing/recommending any test: 
 
isj isj i j i j isj X DT DL U ε β α α + ′ + + = 2 1 ) 4 (;   j = liquid, standard. 
 
The utility from the third alternative (j = no test) is normalized to zero.  
 
In (4), DL is a dummy variable for the liquid based Pap test and DL is a nesting 
dummy for recommending either test (where the base case is no test). Modelling 
intercepts as the only random coefficients is a common way of capturing 
heterogeneity in repeated measures or panel data. How the alternative specific 
intercepts are entered makes no difference in MNL but in MXL different 
specifications imply different covariance structures across choice alternatives (Hall, et 
al., 2006).  The specification in (4), making the coefficients associated with the either 
test dummy and the liquid dummy random, induces correlation across the two test 
choices and choosing the shift dummy for liquid rather than standard is consistent 
with the hypothesis that there is more variability associated with the less commonly 
used test. In the estimation, this assumption is checked by running the alternative 
model with either test and standard dummies. 
 
The Xisj are the other attributes specified in the choice task (both the context attributes 
and the alternative specific attributes). Although there is overlap in the variables 
included in the two experiments, the approach taken to consider the interactive nature 
of decision making is to analyse the decisions of the women and the GPs separately, 
but to assess the extent to which they had similar responses to variables common to 
both choice decisions, and the extent to which attributes of the GP impacted on the 
choices made by women and vice versa.  
 
 
5 Estimation  results 
Log-likelihood values for each of the MXL specifications are compared with the 
standard multinomial logit model in Table 7. Either of the MXL models with the 
intercepts as random coefficients results in a dramatic improvement in fit over the 
15  
MNL models. While these models are nested, the hypothesis tests are non-standard 
because the parameter space is restricted under the alternative. In such situations the 
LR test statistic does not have the usual chi-square asymptotic distribution (Andrews, 
1998). However, in this case the appropriate critical value for the LR test will be 
smaller than the usual chi-square value. Therefore, the LR test statistic for the 
comparison of the MNL and MXL models will lead to rejecting MNL in favor of the 
MXL model at every reasonable significance level. As expected the MXL 
specification with standard as the shift dummy is dominated in terms of fit by the 
specification with liquid as the shift dummy and hence is consistent with our 
hypothesis of higher variability for liquid Pap tests.  Tables 8 and 9 present the results 
for this second MXL model specification for the women and the GPs respectively.  
 
For the women, the mean coefficient for the random intercept for either test was 
positive but not significant, but the mean coefficient for the random intercept for the 
liquid based Pap test was negative and significant. This replicates, for the base case 
with all continuous attributes and demographic variables set to zero and all qualitative 
variables set at their omitted level, the choices of women in the survey where they 
tended to choose the standard Pap test and no test in preference to the liquid based 
test. The standard deviations of both random coefficients are significant, indicating 
heterogeneity among respondents in their preferences for both tests and the presence 
of significant persistence in choices across choice situations. The expected correlation 
between the two tests is captured by the standard deviation associated with the either 
test variable.  
 
In general, the variables included in the experiment were significant and had expected 
signs. Women were less likely to choose a test if the GP was male, or if the GP was 
not their regular GP with the two effects having a similar magnitude. The variables for 
the nationally recommended screening interval suggest that women are responsive to 
the recommended policy – that is, they were more likely to choose a cervical 
screening test if the recommended screening interval was one year (relative to the 
base case of the current screening interval of two years) and less likely to choose a 
test if the recommended screening interval was three or five years. Consistent with 
this, women were responsive to the time since their last test, and were more likely to 
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choose to test if their last screening test was 2 years, 3 years or 5 years ago relative to 
the base case of one year ago. The doctor’s recommendation was also significant. 
Women were more likely to choose to have a cervical screening test if the doctor 
recommended it and to choose a particular test if the doctor recommended it. 
Women’s decisions to screen were not affected by whether their doctor would receive 
an incentive payment or not - this variable had a coefficient that was small and not 
significant in the analysis. 
 
In terms of the alternative specific attributes, all of these were significant and had the 
expected signs. Women were less likely to choose a specific test the more expensive it 
was, and the higher the false positive and false negative rates.  
 
The estimated model also included sociodemographic characteristics: age, education, 
smoking status, country of birth and dummy variables for high and medium 
household incomes. The latter were interacted with the choice to determine if women 
with higher incomes were more likely to choose the liquid based test. Inclusion of the 
sociodemographic characteristics improved the fit of the MXL model indicating 
significant sources of heterogeneity associated with observable differences between 
women in addition to the unobserved heterogeneity captured by the random 
coefficients. The income variables show that women with higher incomes (relative to 
the base case of lower income group) were more likely to choose the liquid based test, 
as the coefficients for both high and medium household incomes when interacted with 
the liquid based test were large and precisely estimated.  Those women who did not 
report their income were much more likely to choose no test in preference to either the 
standard or liquid based test. The remaining sociodemographic characteristics had 
estimated coefficients with signs that were typically as expected but none were 
significant at the 5% level. 
 
For the GPs, the pattern of estimates for both random coefficients is similar to that for 
the women. What is somewhat different is that relative to the estimated means, the 
estimated standard deviations are much smaller for the GPs. This is an indication that 
there is less variability in the GPs recommendations compared to the women’s 
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choices; a result that is not surprising given asymmetry in knowledge and experience 
in making these decisions.  
 
Relative to the base case of a woman who had consulted the doctor specifically for a 
cervical screening test, doctors were less likely to recommend a test if the woman had 
consulted for any other reason. This was the case even if the reason was a general 
check up or a minor health problem, but much less likely if the reason for the 
consultation was a serious health problem. Interestingly, relative to the base case of a 
woman who the GP sees regularly for most of her primary health care, doctors were 
more likely to recommend a cervical screening test at this consultation for a less 
familiar patient. This suggests that doctors are willing to undertake opportunistic 
screening, but are less likely to do so for a woman that they see regularly, perhaps 
because they consider that they are likely to have other opportunities to recommend a 
cervical screening test to women they see regularly for primary health care, or 
because they are more confident about the screening history and behaviour of these 
women.  
 
GPs were highly responsive to the time since a woman last had a cervical screening 
test. Relative to the base case of a year ago, the odds ratio for recommending a test for 
a woman who had had a Pap test 2 years ago, 3 years ago or never were 5.2, 17.8 and 
45.9 respectively.  
 
Relative to the base case of a woman who is less than 20, doctors were significantly 
less likely to recommend a cervical screening test for a woman aged 20-29, a woman 
aged 60-69 and a woman aged 70 or more. The coefficient for women aged 30-59 was 
not significantly different from the base case. Thus, overall, doctors seem more likely 
to screen very young women (who may be more likely to have never screened before) 
and less likely to screen women in the older age groups. Relative to the base case of a 
woman in the lowest socioeconomic group, doctors were less likely to recommend 
screening to women who they perceived to be in higher socioeconomic groups. This 
may be consistent with a perception that opportunistic screening is more important for 
this group, or with perceptions about risk factors for cervical cancer.  
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GPs appeared to be willing to adhere to nationally recommended guidelines. Relative 
to the base case of the current screening interval (two years), doctors were more likely 
to recommend a test if the recommended screening interval was one year, and less 
likely to if the recommended screening interval was three years or five years. By 
contrast, GPs did not appear to respond in the expected manner to practice incentive 
payments. The coefficients for the incentive payment for screening a woman who was 
overdue for a Pap test, or for screening at the recommended screening interval were 
not significant, and the coefficient for an incentive payment for reaching a target 
screening rate of greater than 70% was significant but negative. This counter-intuitive 
result may suggest that doctors responded negatively to the implication that their 
screening recommendations would be influenced by financial incentives.   
 
In terms of the alternative specific attributes, all of these were significant and had the 
expected signs. GPs were less likely to recommend a specific test the more expensive 
it was, and the higher the false positive and false negative rates. 
 
The estimated model also included self-reported characteristics of the GP. The gender 
of the GP was not a significant effect indicating no difference between males and 
females in whether they recommended either test compared to not testing. GPs who 
had been practising for less than one year were less likely to recommend a cervical 
screening test, but otherwise years of practice was not a significant effect. Variables 
were included to reflect the doctor’s own perception of their usual practice in making 
recommendations between different cervical screening tests. These were interacted 
with the recommendation. Doctors who indicated that they mostly recommended the 
standard test were significantly more likely to recommend the standard test, and 
doctors who indicated they mostly recommended the liquid based test were more 
likely to recommend it. However, for doctors who reported that they recommended 
both tests equally, the coefficient for the standard test was not significant, but they 
were significantly more likely to recommend the liquid based test. One possible 
explanation for this is that the scenarios in the choice experiment were more weighted 
towards situations in which these doctors would recommend a liquid based test. 
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In order to further compare the preferences of women in making their choices and the 
GPs when they make their recommendations, Table 10 collects the estimates for 
attributes common to both experiments.  Because these estimates come from separate 
estimations it is important to acknowledge the potential for differences due simply to 
scaling. The scale is normalized on the extreme value errors in each case and there is 
no reason why the degree of heterogeneity reflected in the extreme value errors should 
be the same for the women and the GPs. Table 10 controls for this possibility by 
reporting ratios of coefficients. Ratios that were similar in magnitude would indicate 
the presence of the scaling phenomena and, that after correcting for scale differences 
due to inherent differences in heterogeneity, would indicate women and GPs were 
making the same trade-offs across the common attributes. Another way to control for 
scale is to calculate marginal rates of substitution. These are also provided for the two 
sets of results using the chance of a false negative as the numeraire. 
 
Five of the coefficient ratios are similar in magnitude, which is consistent with the 
hypothesis that scaling explains the differences in the estimated coefficients. 
Moreover, in these cases the ratios are less than one, consistent with the plausible 
result that women exhibit more heterogeneity in their choices compared to that 
associated with the GPs. Thus for both levels of when the patient last had a cervical 
screening test, the chance of a false negative and for the two levels of the 
recommended screening interval greater than two years both women and GPs are on 
average making similar tradeoffs, indicating that in these cases their preferences are 
aligned. Similarly the rates of substitution show how close the tradeoffs of women 
and GPs are for these attributes.  
 
However, the fact that the ratios of estimates for cost, chance of a false positive and if 
the recommended screening interval is one year are all greater than unity indicates 
that this alignment of preferences is not complete. In terms of rates of substitution, 
that for the one year interval is 1.87 times larger for women with the discrepancy even 
more pronounced for the other two attributes. We stress that our results are drawn 
from separate samples and so do not reflect the interaction of a specific GP and 
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patient. Instead we can say that on average, women put relatively more weight on 
these attributes than GPs when making their choices.  
 
    
6 Discussion 
To our knowledge this is the first discrete choice experiment in the health setting to 
examine the interaction of preferences of experts and consumers in a setting where the 
expert (provider) is in an agency relationship with the consumer. A previous paper has 
examined providers’ and women’s preferences for cervical screening programs 
(Arana, et al., 2006) but there, both the women and the providers were being asked 
about their own screening decisions, rather than seeking information about the 
providers’ recommendations. Similarly, other studies have examined issues of agency 
by considering patients’ preferences for characteristics of providers (Vick and Scott, 
1998) but not the interaction of provider and patient preferences. 
 
Our results indicate a considerable commonality in preferences but the alignment was 
not complete. Women put relatively more weight on cost, chance of a false positive 
and if the recommended screening interval is one year. One possible explanation is 
that GPs have inaccurate perceptions of the preferences of their patients. Another 
possibility is that they do correctly perceive the preferences of their patients but shade 
their recommendations in line with their own preferences. Also because of the 
asymmetric information that characterizes the doctor-patient relationship, a GP might 
not recommend the alternative preferred by the patient not because of any 
misperceptions or because of their own self-interest but because they feel, based on 
their superior knowledge, that it is in the best interests of the patient.  
 
It is difficult to determine from our analysis which of these explanations is driving the 
observed differences in preferences. However it is possible to make some plausible 
conjectures. In order to argue that it is inaccurate perceptions by GPs one would have 
to argue why it only occurs for three of the attributes and is not more systematic 
across attributes. Such arguments seem difficult to mount.   
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In the survey, GPs were asked to rate their level of concern about legal action being 
taken against them. On a 7-point Likert scale, only 13% of GPs rated their concern 
about over-screening at one of the three highest levels, while 34% did so for their 
concern about under-screening. Thus the GPs may not be trading off cost and chance 
of false positives as much as women because concerns about litigation lead them on 
average to recommend screening more than women would choose screening when 
faced with the same scenario. But if this is the reason why didn’t it manifest itself in 
other common attributes where, according to our results, women and GPs are making 
similar tradeoffs. More telling is the inconsistency for the attribute associated with the 
recommended screening interval being one year. The fact that women are placing 
relatively higher weight on this attribute indicates they are more likely to choose to 
screen than the GPs are to recommend screening in response to a change from two 
years to one year in the recommended screening interval.   
 
For false positive results and the preferred frequency of screening, GPs are likely to 
be better informed and even though they have accurate perceptions of the preferences 
of women they might shade their recommendations in accord with their view of what 
is in the best interests of their patient. For cost, it is reasonable to expect some doctors 
to consider that it is up to women themselves to decide whether they can afford a 
particular test and that the GP recommendation should give more weight to the health 
and clinical aspects of the decision.   
 
The results also show that there are important aspects of the interaction between the 
patient and the provider that are likely to affect the outcomes of a program such as the 
NCSP. In particular, opportunistic screening is a potentially important way of 
increasing the screening rate, particularly among unscreened or under-screened 
women. Doctors appear willing to engage in opportunistic screening in the sense that 
they are responsive to whether or not they expect to have future opportunities to 
screen the woman (because she is a regular patient), but are unwilling to recommend 
screening to a woman who is consulting for another reason.  By contrast, women are 
more likely to take up screening if it is recommended by the doctor. This appears to 
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provide an opportunity to increase screening rates by encouraging doctors to 
recommend screening even when the woman is attending for another reason, 
particularly a general health check or a minor health problem. However, an interesting 
challenge is created by the fact that women are less likely to take up a screening 
opportunity if they are unfamiliar with the doctor, whereas doctors are more likely to 
recommend screening to women who are not their regular patients. 
 
While the results suggest that providers are not responsive to financial incentives (and 
indeed may respond perversely to them) caution needs to be applied in interpreting 
this result. It may suggest that a choice experiment, which relies on self report of 
intended behaviour, is not an effective mechanism to assess the impact of financial 
incentives of this type.      
 
The results suggest that changes to the recommended screening interval are not likely 
to result in perverse behaviour (contrary to recommendations) for either women or 
general practitioners. Thus, the concern that a change to the screening interval may 
undermine confidence in the screening program appears unfounded. Both doctors and 
patients appear likely to follow national recommendations although, as we have noted, 
the doctors were less likely to screen than women when the recommendation was one 
year.  
 
While there has been considerable discussion over the past decade about the merits of 
a more accurate screening test, these results do not indicate strong support among 
either women or GPs for the liquid based test, especially if it is more expensive. 
While both groups have a preference for increased accuracy, this does not translate 
into a preference for the liquid based test per se, in the sense that the labelled 
alternative of the liquid based test was chose in less than 25% of choice sets for both 
women and general practitioners. 
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At present we have only considered the preferences of women who have previously 
participated in screening. An important extension of the current work will be to 
examine the preferences of the never-screened women. 
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Table 1: Example of a choice task for the women’s sample 
 
You are visiting the GP who gives you some information about Pap tests and raises the issue of having 
a Pap test. 
 
About this GP: 
This GP is   your regular GP who you 
usually see for most care, 
including Pap tests 
This GP is   Female 
This GP’s practice will receive a special incentive 
payment if you have a Pap test at this visit  No 
 
About the tests available: 
 Standard  Pap 
test 
Liquid based 
Pap test  
The out of pocket costs to you for this test will be  $0  $20 
The chance that this test will give you a false 
negative result is  1 in 20  1 in 33 
The chance that this test will give you a false 
positive result is  1 in 1000  1 in 500 
 
Other information the GP gives you about cervical screening: 
The GP tells you that you had your last Pap test  about 1 year ago 
The national recommendation is that women should 
have a Pap test  every 1 year 
If you have either Pap test you can at the same time 
have an HPV test at an additional out-of-pocket cost 
to you of  
$50 
The GP recommends that  you do not have a Pap test at 
this visit 
The GP recommends that you  do not have the HPV test 
 
At this visit to the GP what would you choose to do? 
Circle the number next to your choice 
 
I would not have a cervical cancer screening test 
 
I would have a standard Pap test 
 








Circle Yes or No to show your choice 
 
If you chose to have a Pap test, would you also have the HPV test at 








Table 2: Example of choice task for the general practitioners sample 
 
A female patient is attending your practice for a primary care consultation 
 
About this patient: 
This patient is attending the consultation  for a minor health problem 
This patient is  a patient who has previously 
consulted your practice but has 
not consulted you 
This patient last had a Pap test   about 3 years ago 
This patient is aged  Less than 20 
In your perception this patient is in  the middle income/SES range 
 
About the tests available: 
 Standard  Pap 
test 
Liquid based 
Pap test  
The out-of-pocket costs to the patient for this test will be 
  $0 $20 
The chance that this test will give a false negative result 
is  1 in 10  1 in 10 
The chance that this test will give a false positive result 
is  1 in 150  1 in 100 
 
Other information about cervical screening: 
The national recommendation is that women should have 
a Pap test  every 3 years 
If the patient has a Pap test at this consultation, your 
practice will receive 
 
a standard consultation fee and an 
incentive payment if the patient 
has a Pap test at the recommended 
screening interval 
At the same time that the patient has a Pap test it is 




What would you recommend to this patient with regard to a Pap test at this 
consultation? 
Circle the number next to your choice 
I would not recommend the patient have a cervical cancer screening test at 
this consultation 
 
I would recommend the patient have a standard Pap test at this 
consultation 
 












Circle Yes or No to show your choice 
If you recommended that the patient have a Pap test, would you also 







Table 3: Attributes, levels and corresponding names for the women’s survey 
Context Attributes  Levels  Names 
•  1 year  recint1 
•  2 years  Base 
•  3 years  recint2 
The recommended screening 
interval 
 
•  5 years  recint3 
•  Your regular GP who you 
usually see for most care, 
including Pap tests;  
Base  This general practitioner is  
 
•  A GP you do not usually 
see, or have not seen 
before 
Knowgp 
•  Female  Base  This general practitioner is 
  •  Male  Sexgp 
•  About 1 year ago  Base 
•  About 2 years ago  testdue1 
•  About 3 years ago  testdue2 
Your doctor tells you had your last 
cervical screening test 
 
•  About 5 years ago  testdue3 
•  You do not have a cervical 
screening test today 
Base 
•  You have the standard Pap test 
today  
drrrec1 
•  You have the liquid based 
cytology Pap test today 
drrrec1 




•  You have a cervical screening 
test today but does not 
recommend one test over the 
other 
drrrec2 
•  No  Base  Your doctor will receive a special 
payment if you have a cervical 
screening test  •  Yes  Drink 
 













Cost of the test to the patient 
 
$0, $10, $20, $30 (A)  A+$10, A+$20, 
A+$30, A+$40 
Cost 
The chance that this test will 
give a false negative result 
 
1 in 20 (5%), 1 in 15 
(6.67%), 1 in 10 (10%), 
1 in 5 (20%) 
1 in 100 (1%), 1 in 
33 (3.03%), 1 in 20 
(5%), 1 in 10 (10%) 
Fneg 
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The chance that this test will 
give a false positive result  
 
1 in 1000 (0.1%), 1 in 
250 (0.4%), 1 in 150 
(0.67%), 1 in 100 (1%) 
1 in 2000 (0.05%), 1 
in 500 (0.2%), 1 in 




•  The attributes and levels pertaining to the HPV test are not reported in this table as they are 
not used in the analysis presented in this paper. For completeness, they appear in the example 
choice task (table 1). 
•  All variables, except cost ($), fneg (%) and fpos (%), have been dummy coded in the 
estimation. 
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Table 4: Attributes, levels and corresponding names for the GP survey 
Context Attributes  Levels  Names 
•  Specifically for a cervical screening test  Base 
•  For a general check-up  consult1 
•  For a minor health problem  consult2 
The patient is attending this 
consultation  
 
•  For a serious health problem  consult3 
•  1 year  recint1 
•  2 years  Base 
•  3 years  recint2 
The recommended 
screening interval is every 
 
•  5 years  recint3 
•  a patient who consults you for most of 
her primary health care including Pap 
tests 
Base 
•  a patient who has consulted you regularly 
but not previously for a Pap test 
knowpat1 
•  a patient who has previously consulted 
your practice, but has not consulted you 
knowpat2 






•  a new patient to your practice  knowpat3 
•  About 1 year ago  Base 
•  About 2 years ago  testdue1 
•  About 3 years ago  testdue2 
This patient last had a 
cervical screening test  
 
•  Never  testdue3 
•  Less than 20 years old  Base 
•  20-29  agepat1 
•  30-59  agepat2 
•  60-69  agepat3 




•  70 or more years old  agepat4 
•  In the lowest income/SES range  Base 
•  In the low-middle income/SES range  sespat1 
•  In the middle income/SES range  sespat2 
Your perception of this 
patient’s household income 
 
•  In the highest income/SES range  sespat3 
•  A standard consultation fee only  Base 
•  A standard consultation fee, and an 
incentive payment if the woman is 
overdue for a Pap test by 12 months or 
more 
payment1 
•  A standard consultation fee, and an 
incentive payment if the woman has a 
Pap test at the recommended screening 
interval 
payment2 
Payment to your practice for 









•  A standard consultation fee, and an 
incentive payment if the practice achieves 
a screening rate of 70% or  more of the 



















Cost of the test to the patient 
 
$0, $10, $20, $30 (A)  A+$10, A+$20, 
A+$30, A+$40 
Cost 
The chance that this test will 
give a false negative result 
 
1 in 20 (5%), 1 in 15 
(6.67%), 1 in 10 (10%), 
1 in 5 (20%) 
1 in 100 (1%), 1 in 
33 (3.03%), 1 in 20 
(5%), 1 in 10 (10%) 
Fneg 
The chance that this test will 
give a false positive result  
 
1 in 1000 (0.1%), 1 in 
250 (0.4%), 1 in 150 
(0.67%), 1 in 100 (1%) 
1 in 2000 (0.05%), 1 
in 500 (0.2%), 1 in 




•  The attributes and levels pertaining to the HPV test are not reported in this table as they are 
not used in the analysis presented in this paper. For completeness, they appear in the example 
choice task (table 2). 








Table 5: Sociodemographic variables, levels, and corresponding names, 
means or percentages by sample 
  
Variables Levels  Names  Means/percentages 
  Women 
Age In  years  age  42 
•  Some primary to 
completed secondary 
Base 54% 
•  Trade  ed_trade 16% 
•  Some university  ed_some uni 10% 
Education 
•  Completed 
university 
ed_high 20% 
•  Up to $50,000  Base 63% 
•  $50,001 to $80,000  inc_med 16% 
•  Over $80,000  inc_high 14% 
Household 
Income 
•  Income not reported  inc_mis 7% 
•  Australia  Base 86%  Country of birth 
•  Other  cob 14% 
•  Never regular  Base 54% 
•  Current smoker  smoke_curr 23% 
Smoking 
•  Ex-smoker  smoke_ex 23% 
      
  GP 
•  Mostly liquid based 
pap test 
recom_liq 14% 
•  Mostly standard pap 
test 
recom_std 55% 




of tests to patients 
having a cervical 
screening test in 
the past year 
•  No preference of one 
test over another 
Base 9% 
•  Female  Base 54%  Gender 
•  Male  gender 46% 
•  Less than 1 year  prac1 7% 
•  1-5 years  prac2 20% 
•  6-10 years  Base 18% 
•  11-20 years  prac3 28% 
GP practice years 
•  More than 20 years  prac4 27% 










Table 6: Choice response frequencies 
 
  Women GPs 
 Freq  %  Freq  % 
No test  1991  37.3%  2947  42.8% 
Standard pap test  2088  39.1%  2232  32.4% 
Liquid based test  1265  23.7%  1701  24.7% 




Table 7: Log-likelihood values for MNL and MXL Models 
Model Log-Likelihood 
 Women  GPs 
MNL -5240.97  -5491.35 
MXL (test & standard Pap intercepts)  -3844.58  -4935.48 
MXL (test & liquid Pap intercepts)  -3842.12  -4886.78 


















































Variables    Estimates p-value 
Intercepts
either test  Mean  0.7054 0.2738 
  Std. Deviation  2.3273 <0.0000 
liquid test  Mean  -1.1300 0.0005 
  Std. Deviation  2.5850 <0.0000 
Context attributes
sexgp    -0.9210  <0.0000 
knowgp    -0.9846  <0.0000 
recint1    0.4111  <0.0000 
recint2    -0.4234  <0.0000 
recint3    -1.0818  <0.0000 
testdue1    1.1063  <0.0000 
testdue2    1.4281  <0.0000 
testdue3    2.0718  <0.0000 
drrec1
a   0.8869  <0.0000 
drrec2    0.7633  <0.0000 
drinc    -0.0656 0.2844 
Alternative specific attributes
cost    -0.0268  <0.0000 
fneg    -0.0321  <0.0000 
fpos    -0.4504  <0.0000 
Sociodemographic attributes
age    0.0169 0.1364 
ed_trade    -0.7230 0.0718 
ed_some uni    -0.6057 0.2447 
ed_high    -0.3050 0.5217 
inc_med  Standard test
b
0.4845 0.4389 
inc_med  Liquid test  1.8528 <0.0000 
inc_high  Standard test  -0.0591 0.9047 
inc_high  Liquid test  1.8208 0.0079 
inc_mis  Standard test  -1.2123 0.0393 
inc_mis  Liquid test  -1.9796 <0.0000 
Cob    0.1262 0.7786 
smoke_curr    -0.1959 0.7173 
smoke_ex    -0.4472 0.2003 
Notes:  
•  Refer to the tables 3 and 5 for more descriptions of the variables.  
• 
a For the utility function of the standard test, drrec = 1 if the doctor 
recommended standard test and for the utility function of the liquid test, drrec 
= 1 if the doctor recommended liquid test.  
• 
b Modeling the effect of the corresponding income level on this specific test. 
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Table 9: Estimated results for the Mixed logit specification for GPs 
Variables    Estimates p-value 
Intercepts
either test  Mean  1.6301  <0.0000 
  Std. Deviation  1.1312  <0.0000 
liquid test  Mean  -0.9906  <0.0000 
  Std. Deviation  1.5690  <0.0000 
Context attributes
consult1   -2.2893  <0.0000 
consult2   -1.9908  <0.0000 
consult3   -3.7900  <0.0000 
knowpat1   0.6137  <0.0000 
knowpat2   0.3018 0.0060 
knowpat3   0.3003 0.0006 
testdue1   1.7285  <0.0000 
testdue2   2.7981  <0.0000 
testdue3   3.7663  <0.0000 
agepat1   -0.5294 0.0001 
agepat2   0.1007 0.3752 
agepat3   -0.9762  <0.0000 
agepat4   -2.3698  <0.0000 
recint1   0.4013 0.0001 
recint2   -0.7646  <0.0000 
recint3    -1.6122  <0.0000 
payment1    0.1132 0.2344 
payment2    -0.0909 0.3930 
payment3    -0.4290 <0.0000 
sespat1    -0.2895 0.0042 
sespat2    -0.0842 0.4134 
sespat3    -0.3030 0.0038 
Alternative specific attributes
Cost    -0.0134  <0.0000 
Fneg    -0.0586  <0.0000 
fpos    -0.3471  <0.0000 
Sociodemographic attributes
gender    0.0055 0.9753 
prac1   -1.2120 0.0006 
prac2   -0.1190 0.6051 
prac3   -0.0387 0.8528 
prac4    -0.2888 0.2480 
recom_std  Standard test
 a
0.6425 0.0013 
recom_liq Liquid  test
 
2.4135 <0.0000 
recom_eq Standard  test  0.3551 0.2082 





•  Refer to the tables 4 and 5 for more descriptions of the variables.  
• 




Table 10: Comparing MXL estimates of common attributes 
 
  Estimates  Rates of substitution 
Attribute GP    Women  Ratio* GP    Women  Ratio* 
False  negative -0.06  -0.03  0.55 1.00 1.00 1.00 
False positive   -0.35  -0.45  1.30  5.92  14.02  2.37 
Cost  -0.01  -0.03  1.99 0.23 0.83 3.64 
Interval 1 yr  0.40  0.41  1.02  -6.84  -12.80  1.87 
Interval 3 yrs  -0.76  -0.42  0.55  13.04  13.18  1.01 
Interval 5 yrs  -1.61  -1.08  0.67  27.49  33.68  1.23 
Last test 2 yrs  1.73  1.11  0.64  -29.47  -34.44  1.17 
Last test 3 yrs  2.80  1.43  0.51  -47.71  -44.46  0.93 
* Women’s value divided by GP value   
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